


Selection criteria of TKIs in 1L or 2L after atezolizumab+bevacizumab for advanced or unresectable HCC patients



Abbreviations:

1L, first line; 2L, second line; AE, adverse event; BCCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; HR, hazard ratio; mOS, median overall survival; ORR, objective response rate; (m)RECIST, (modified) response evaluation criteria in solid tumours; TEAES, treatment-emergent adverse events; TKI, tyrosine kinase inhibitor

References:

Finn RS et al. N Engl J Med. 2020;382(20):1894-905. Llovet JM et al. N Engl J Med. 2008;359(4):378-90.

Kudo M et al. Lancet. 2018;391(10126):1163-73. Kudo et al. ILCA 2021 Poster #P-34

Gordan JD et al. J Clin Oncol. 2020;43:17-4345. Vogel A et al. Ann Oncol. 2021;8:801-805